[Use of recombinant alpha2-interferon in combination with myelosan for the treatment of patients with chronic myeloid leukemia].
The authors present results of chronic myeloid leukemia (CML) treatment with recombinant and leukocytic interferon in monotherapy and in combination with myelosan. The best responses (72% of complete hematological remissions) were obtained in patients pretreated with myelosan (one course of 1-1.5 months) in combination with natural antioxidants.
Petukhov
V I
VI
Strozha
I
I
Bondare
D K
DK
Feldmane
G Ia
GIa
Mauritsas
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins; D002066:Busulfan
Primenenie rekombinantnogo alpha2-interferona v sochetanii s mielosanom dlia lecheniia bol'nykh khronicheskim mieloleĭkozom.